Literature DB >> 28732137

Prevalence of Sacroiliitis in Inflammatory Bowel Disease Using a Standardized Computed Tomography Scoring System.

Jonathan Chan1, Ismail Sari2, David Salonen3, Mark S Silverberg4, Nigil Haroon5, Robert D Inman5.   

Abstract

OBJECTIVE: There is an increasing emphasis on the early identification and treatment of ankylosing spondylitis (AS) of which the hallmark is sacroiliitis. Patients with inflammatory bowel disease (IBD) are at increased risk of AS and often receive computed tomography (CT) scans of their abdomen, affording clinicians the opportunity to determine the presence of sacroiliitis. Previous studies using CT have relied only on the radiologist's gestalt or a nonvalidated adaptation of the modified New York criteria. Our aim is to assess the prevalence of sacroiliitis in IBD using a validated screening tool and to determine how frequently these patients are referred for rheumatologic evaluation.
METHODS: Patients with IBD were recruited from an IBD clinic. Control patients were recruited from a urology clinic and were confirmed to be without back pain, spondylitis, psoriasis, colitis, or uveitis by chart review. CT scans were read by 2 blinded readers and sacroiliitis was defined by the presence of ankylosis or a total erosion score of ≥3.
RESULTS: CT scans were available in 233 Crohn's disease (CD) patients, 83 ulcerative colitis (UC) patients, and 108 control patients, and sacroiliitis was seen in 15%, 16.9%, and 5.6% of patients, respectively. The prevalence was higher in patients with IBD than in controls (P = 0.007), with no significant difference between CD and UC patients. Of the 49 IBD patients found to have sacroiliitis by CT scan, only 5 had been referred to a rheumatologist.
CONCLUSION: There is a 3-fold higher prevalence of sacroiliitis in IBD compared with controls. Despite a growing awareness of this increased prevalence, many patients are not referred to a rheumatologist.
© 2017, American College of Rheumatology.

Entities:  

Mesh:

Year:  2018        PMID: 28732137     DOI: 10.1002/acr.23323

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  7 in total

Review 1.  Epidemiology of axial spondyloarthritis: an update.

Authors:  Runsheng Wang; Michael M Ward
Journal:  Curr Opin Rheumatol       Date:  2018-03       Impact factor: 5.006

Review 2.  Prevalence of axial spondyloarthritis in patients with inflammatory bowel disease using cross-sectional imaging: a systematic literature review.

Authors:  Jobie Evans; Mark Sapsford; Scott McDonald; Kenneth Poole; Tim Raine; Deepak R Jadon
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-03-11       Impact factor: 5.346

3.  From bowel inflammation to the bone and joints: musculoskeletal examination in inflammatory bowel disease (IBD).

Authors:  Samane Tavassoli; Iman Shahabinasab; Alireza Norouzi; Taghi Amiriani; Nafiseh Abdolahi; Somayeh Livani; Seyed Farzam Mirkamali; Honey Sadat Mirkarimi; Fazel Isapanah Amlashi; Sima Besharat
Journal:  BMC Musculoskelet Disord       Date:  2021-12-04       Impact factor: 2.362

4.  Sacroiliac joint involvement in children with inflammatory bowel diseases.

Authors:  Nelgin Gerenli; Betul Sozeri; Sevinc Kalin; Heves Kirmizibekmez; Coskun Celtik
Journal:  North Clin Istanb       Date:  2021-02-08

5.  Subclinical sacroiliitis detected by abdominopelvic computed tomography in Korean patients with Crohn's disease.

Authors:  You-Jung Ha; Hyo Jin Kim; Eugene Lee; Ji Hye Park; Young Soo Park; Yun Jong Lee; Yusuhn Kang; Hyuk Yoon
Journal:  Korean J Intern Med       Date:  2021-03-22       Impact factor: 2.884

6.  Axial spondyloarthritis 10 years on: still looking for the lost tribe.

Authors:  Rosemarie Barnett; Thomas Ingram; Raj Sengupta
Journal:  Rheumatology (Oxford)       Date:  2020-10-01       Impact factor: 7.580

7.  Temporal Relationship of Extraintestinal Manifestations in Inflammatory Bowel Disease.

Authors:  Istvan Fedor; Eva Zold; Zsolt Barta
Journal:  J Clin Med       Date:  2021-12-20       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.